Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

S8451

Sigma-Aldrich

Saquinavir mesylate

≥98% (HPLC), powder

Sinonimo/i:

(2S)-N1[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-Dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide methanesulfonate, Ro-31-8959

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C38H50N6O5·CH4O3S
Numero CAS:
Peso molecolare:
766.95
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

Saggio

≥98% (HPLC)

Forma fisica

powder

Condizioni di stoccaggio

desiccated

Colore

white to tan

Solubilità

DMSO: ≥5 mg/mL

Ideatore

Roche

Temperatura di conservazione

2-8°C

Stringa SMILE

CS(O)(=O)=O.CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(N)=O)NC(=O)c4ccc5ccccc5n4

InChI

1S/C38H50N6O5.CH4O3S/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29;1-5(2,3)4/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49);1H3,(H,2,3,4)/t26-,27+,30-,31-,32-,33+;/m0./s1
IRHXGOXEBNJUSN-YOXDLBRISA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Saquinavir is a peptidomimetic hydroxyethylamine inhibitor, which is used to treat human immunodeficiency virus (HIV) infection.

Applicazioni

Saquinavir mesylate may be used in cell signaling and immunology studies.

Azioni biochim/fisiol

Saquinavir is an HIV Protease Inhibitor used in antiretroviral therapy. It inhibits both HIV-1 and HIV-2 proteases. Studies have also looked at saquinavir as a possible anti-cancer agent.

Caratteristiche e vantaggi

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Lopinavir ≥98% (HPLC)

Sigma-Aldrich

SML1222

Lopinavir

Lonafarnib ≥98% (HPLC)

Sigma-Aldrich

SML1457

Lonafarnib

Cepharanthine ≥95% (HPLC)

Sigma-Aldrich

SML1269

Cepharanthine

vibrant-m

Y0001498

Lopinavir

Lamivudine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1365

Lamivudine

Marija Mojic et al.
Molecular pharmacology, 82(4), 700-710 (2012-07-17)
We have examined the influence of the nitric oxide (NO)-modified anti-inflammatory drug (S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid (VGX-1027) named GIT-27NO or the NO-modified antiviral drug saquinavir (Saq) named Saq-NO on two colon cancer cell lines, mouse CT26CL25 and human HCT116. The effects
Shigeyoshi Harada et al.
The Journal of general virology, 94(Pt 5), 933-943 (2013-01-05)
The initiation of drug therapy results in a reduction in the human immunodeficiency virus type 1 (HIV-1) population, which represents a potential genetic bottleneck. The effect of this drug-induced genetic bottleneck on the population dynamics of the envelope (Env) regions
Atsuko Tomaru et al.
Drug metabolism and pharmacokinetics, 30(3), 221-226 (2015-04-18)
Modulation of CYP3A and/or P-gp function by several excipients has been reported. However, relatively few studies have investigated their effects in humans. Therefore, the aim of this clinical study was to clarify the effects of Cremophor EL on the inhibition
Yung-Chih Kuo et al.
Colloids and surfaces. B, Biointerfaces, 101, 101-105 (2012-07-17)
Application of cationic solid lipid nanoparticles (CSLNs), comprising complex internal matrix and lipid-regulated external surface, is an intriguing issue in current bionanotechnology. This study presents dissolution kinetics of saquinavir (SQV) from CSLNs with cholesterol-mediated esterquat 1 (EQ 1) and biocompatibility
Martha Stefanidou et al.
Antimicrobial agents and chemotherapy, 56(8), 4381-4390 (2012-06-06)
The maturation of newly formed human immunodeficiency virus type 1 (HIV-1) virions is a critical step for the establishment of productive infection. We investigated the potential of saquinavir (SQV), a protease inhibitor (PI) used in highly active antiretroviral therapy (HAART)

Articoli

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Discover Bioactive Small Molecules for ADME/Tox

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.